HTC
LCTX icon

Haverford Trust Company’s Lineage Cell Therapeutics LCTX Stock Holding History

Haverford Trust Company’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-13,612
Closed -$15K – 337
2022
Q3 		$15K Buy
+13,612
New +$20K ﹤0.01% 332

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Haverford Trust Company's LCTX Position: Q4 2022 in Review

Haverford Trust Company sold out of Lineage Cell Therapeutics (LCTX) in Q4 2022, closing a stake of 13,612 shares — an estimated $15K sold.

Haverford Trust Company first reported a position in LCTX in Q3 2022 and held it in 1 quarter. The position peaked at $15K in Q3 2022. 106 funds tracked by Wall St. Rank hold LCTX as of Q4 2022.

  • Haverford Trust Company reported no remaining Lineage Cell Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Haverford Trust Company sold 13,612 Lineage Cell Therapeutics shares in Q4 2022, an estimated $15K.
  • Haverford Trust Company first reported a position in Lineage Cell Therapeutics in Q3 2022 and held it in 1 quarter.
  • Haverford Trust Company's Lineage Cell Therapeutics position peaked at $15K in Q3 2022.
  • 106 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2022.

Based on Haverford Trust Company's 13F filing for Q4 2022, filed 13 Feb 2023.